Prestige Consumer Healthcare Inc. (PBH) Stock Price

PBHStock

$49.92−19.24%52W

Market Cap$2.36B

P/E12.43x

PEG Ratio1.53

Div yield—

Beta0.30

PBH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-21.80%

Price vs S&P 500 (4W)7.99%

PEG Ratio1.53

VGM Score57.13

P/E Ratio (Annual)12.43x

P/CF (Annual)9.18x

Book Value / Share (Quarterly)$40.46

Revenue Growth (3Y)-1.17%

Cash Flow / Share (Quarterly)$4.97

Price vs S&P 500 (YTD)-31.01%

Gross Margin (TTM)53.53%

Net Profit Margin (TTM)15.57%

EPS (TTM)$3.57

10-Day Avg Trading Volume0.53M

EPS Excl Extra (TTM)$3.57

Revenue Growth (5Y)2.91%

EPS (Annual)$3.91

ROI (Annual)6.55%

Gross Margin (Annual)54.71%

Net Profit Margin (5Y Avg)13.31%

Cash / Share (Quarterly)$1.88

P/E Basic Excl Extra (TTM)13.75x

Revenue Growth QoQ (YoY)6.48%

EPS Growth (5Y)3.71%

P/E Normalized (Annual)12.43x

ROA (Last FY)5.45%

Revenue Growth TTM (YoY)-1.36%

EBITD / Share (TTM)$6.47

ROE (5Y Avg)8.35%

Operating Margin (TTM)26.26%

Cash Flow / Share (Annual)$5.21

P/B Ratio1.23x

P/B Ratio (Quarterly)1.17x

Net Income / Employee (Annual)$317,200

EV / Revenue (TTM)3.91x

Net Interest Coverage (TTM)7.08x

ROA (TTM)4.59%

EPS Growth QoQ (YoY)-35.65%

EV / EBITDA (TTM)13.85x

EPS Incl Extra (Annual)$3.91

Current Ratio (Annual)3.57x

Quick Ratio (Quarterly)1.80x

3-Month Avg Trading Volume0.59M

52-Week Price Return-19.24%

EV / Free Cash Flow (Annual)17.52x

P/E Incl Extra (TTM)13.75x

Revenue / Employee (TTM)$1,841,500

Tangible BV / Share (Quarterly)$-26.59

P/S Ratio (Annual)2.17x

Asset Turnover (Annual)0.31x

52-Week High$71.07

Operating Margin (5Y Avg)23.32%

EPS Excl Extra (Annual)$3.91

CapEx CAGR (5Y)-12.82%

26-Week Price Return-11.90%

Quick Ratio (Annual)2.12x

13-Week Price Return0.00%

Total Debt / Equity (Annual)0.54x

Current Ratio (Quarterly)3.23x

Enterprise Value$4.32B

Revenue / Share Growth (5Y)3.69%

Asset Turnover (TTM)0.29x

Book Value / Share Growth (5Y)7.94%

Revenue / Employee (Annual)$1,814,500

Inventory Turnover (Annual)3.21x

Pretax Margin (Annual)23.65%

Cash / Share (Annual)$1.35

3-Month Return Std Dev31.30%

Gross Margin (5Y Avg)55.70%

Net Income / Employee (TTM)$286,700

EBITDA CAGR (5Y)1.35%

EBITDA Interim CAGR (5Y)-9.73%

ROE (Last FY)10.08%

Net Interest Coverage (Annual)6.08x

EPS Basic Excl Extra (Annual)$3.91

P/FCF (TTM)10.05x

Receivables Turnover (TTM)6.21x

EV / Free Cash Flow (TTM)18.34x

Total Debt / Equity (Quarterly)1.06x

EPS Incl Extra (TTM)$3.57

Receivables Turnover (Annual)5.64x

ROI (TTM)5.47%

P/S Ratio (TTM)2.14x

Pretax Margin (5Y Avg)17.80%

Revenue / Share (Annual)$22.35

Tangible BV / Share (Annual)$-28.62

Forward P/E10.89x

Free OCF CAGR (5Y)2.92%

Price vs S&P 500 (52W)-34.77%

P/E Ratio (TTM)13.75x

EPS Growth TTM (YoY)-16.21%

Year-to-Date Return-19.08%

5-Day Price Return1.88%

EPS Normalized (Annual)$3.91

ROA (5Y Avg)4.24%

Net Profit Margin (Annual)17.48%

Month-to-Date Return8.83%

Cash Flow / Share (TTM)$-1.01

EBITD / Share (Annual)$6.78

EPS Growth (3Y)1.99%

Operating Margin (Annual)28.42%

LT Debt / Equity (Annual)0.53x

P/CF (TTM)9.48x

ROI (5Y Avg)5.07%

P/E Excl Extra (TTM)13.75x

LT Debt / Equity (Quarterly)1.05x

EPS Basic Excl Extra (TTM)$3.57

P/B Ratio (Annual)1.49x

Inventory Turnover (TTM)2.99x

Pretax Margin (TTM)21.20%

Book Value / Share (Annual)$39.89

Price vs S&P 500 (13W)-2.69%

Net Margin Growth (5Y)0.02%

Beta0.30x

P/FCF (Annual)9.60x

Revenue / Share (TTM)$23.21

ROE (TTM)9.22%

52-Week Low$42.62

vGradeB

gGradeC

mGradeB

vgmGradeC

PBH Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	$0.88	$0.98	+12.00%(+$0.10)
Q1 2026	May 13, 2026	$1.39	$1.23	-11.51%(-$0.16)
Q4 2025	Feb 5, 2026	$1.16	$1.14	-1.36%(-$0.02)
Q3 2025	Nov 6, 2025	$0.97	$0.86	-11.34%(-$0.11)
Q2 2025	Aug 7, 2025	$0.99	$0.95	-4.23%(-$0.04)

PBH Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PBHPrestige Consumer Healthcare Inc.	B	C	B	2.1x	-1.4%	53.5%	3.7%	$49.92
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare is a leading pure-play OTC healthcare provider with a portfolio of category-dominant brands including Clear Eyes, Dramamine, Monistat, and Summer's Eve. These brands maintain strong market positions backed by healthcare professional endorsements. The company generates approximately 85% of revenue from North America, with the remainder from Australia, New Zealand, and select Asian markets.

PBH Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$1.07

Revenue estimate$329.13M

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

NGVTIngevity CorporationChemicals
ADMAADMA Biologics, Inc.Biological Products
IOSPInnospec Inc.Chemicals
ROGRogers CorporationPlastics & Resins
CLDXCelldex Therapeutics, IncIn Vitro Diagnostics
VCELVericel CorporationBiological Products
BCRXBioCryst Pharmaceuticals IncBiological Products
MTXMinerals Technologies IncIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.0

Buy

Consensus rating

52-Week Range

Low$42.62

High$71.07